Given the fact that SOX4 has an established oncogenic role across multiple malignancies and in EMT processes, the ability of miR-19a-3p to suppress SOX4 further underscores its relevance as a promising therapeutic and biomarker candidate in PCa [16]. Here, SOX4 is linked to posterior cortical atrophy.